Symbols / ADCT Stock $3.43 -1.44% ADC Therapeutics SA

Healthcare • Biotechnology • Switzerland • NYQ
ADCT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Ameet Mallik M.B.A., M.S.
Exch · Country NYQ · Switzerland
Market Cap 436.27M
Enterprise Value 641.52M
Income -136.99M
Sales 79.17M
FCF (ttm) -74.85M
Book/sh -1.70
Cash/sh 1.82
Employees 188
Insider 10d —
IPO May 18, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.30
PEG —
P/S 5.51
P/B -2.02
P/C —
EV/EBITDA -6.29
EV/Sales 8.10
Quick Ratio 3.88
Current Ratio 4.09
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.97
EPS next Y -1.49
EPS Growth —
Revenue Growth -9.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-04
ROA -22.73%
ROE —
ROIC —
Gross Margin -26.33%
Oper. Margin -121.07%
Profit Margin -173.02%
Shs Outstand 127.19M
Shs Float 100.41M
Insider Own 13.25%
Instit Own 66.61%
Short Float 4.77%
Short Ratio 6.10
Short Interest 5.14M
52W High 4.98
vs 52W High -31.12%
52W Low 1.25
vs 52W Low 173.52%
Beta 1.84
Impl. Vol. 10.48%
Rel Volume 1.18
Avg Volume 1.01M
Volume 1.20M
Target (mean) $8.20
Tgt Median $8.00
Tgt Low $6.00
Tgt High $10.00
# Analysts 5
Recom Strong_buy
Prev Close $3.48
Price $3.43
Change -1.44%
About

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.20
Mean price target
2. Current target
$3.43
Latest analyst target
3. DCF / Fair value
$-10.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.43
Low
$6.00
High
$10.00
Mean
$8.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-05 reit RBC Capital Outperform → Outperform $6
2026-05-05 reit HC Wainwright & Co. Buy → Buy $8
2026-03-23 main HC Wainwright & Co. Buy → Buy $8
2025-10-16 main HC Wainwright & Co. Buy → Buy $7
2025-08-13 reit Guggenheim Buy → Buy $10
2025-06-20 main RBC Capital Outperform → Outperform $5
2025-06-13 main Guggenheim Buy → Buy $10
2025-05-15 reit RBC Capital Outperform → Outperform $8
2025-03-31 main Guggenheim Buy → Buy $7
2025-03-31 reit HC Wainwright & Co. Buy → Buy $8
2025-03-07 reit Cantor Fitzgerald Overweight → Overweight —
2025-02-24 main Stephens & Co. Overweight → Overweight $8
2025-01-06 reit HC Wainwright & Co. Buy → Buy $8
2024-12-12 reit Guggenheim Buy → Buy $10
2024-12-11 reit HC Wainwright & Co. Buy → Buy —
2024-11-08 init Stephens & Co. — → Overweight $6
2024-08-08 reit HC Wainwright & Co. Buy → Buy $8
2024-08-07 reit RBC Capital Outperform → Outperform $8
2024-05-30 init Cantor Fitzgerald — → Overweight —
2024-05-07 main HC Wainwright & Co. Buy → Buy $8
News
RSS: Latest ADCT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-02 REDMILE GROUP, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 5,880,415 $3.28 $19,636,340
2026-02-13 GRAHAM PETER J Officer — 294,800 $3.99 $1,176,252
2026-02-13 CARMONA JOSE Chief Financial Officer — 271,600 $3.99 $1,083,684
2026-02-13 MALLIK AMEET Chief Executive Officer — 900,000 $3.99 $3,591,000
2026-02-13 ZAKI MOHAMED Officer — 285,200 $3.99 $1,137,948
2026-02-13 KALLEBO LISA MICHELLE Officer — 62,900 $3.99 $250,971
2025-06-03 COUGHLIN TIMOTHY P Director — 40,000 $0.00 $0
2025-06-03 SQUARER RON R Director — 40,000 $0.00 $0
2025-06-03 BIZZARI JEAN-PIERRE Director — 40,000 $0.00 $0
2025-06-03 SANDOR VICTOR Director — 40,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
81.36
+14.85%
70.84
+1.84%
69.56
-66.86%
209.91
Operating Revenue
81.36
+14.85%
70.84
+1.84%
69.56
-66.86%
209.91
Cost Of Revenue
5.80
-2.54%
5.95
+135.23%
2.53
-23.39%
3.30
Reconciled Cost Of Revenue
5.80
-2.54%
5.95
+135.23%
2.53
-23.39%
3.30
Gross Profit
75.56
+16.45%
64.89
-3.19%
67.03
-67.56%
206.61
Operating Expense
182.77
-6.02%
194.48
-16.20%
232.08
-29.59%
329.59
Research And Development
104.00
-5.13%
109.63
-13.76%
127.13
-31.82%
186.46
Selling General And Administration
79.93
-6.96%
85.91
-18.87%
105.89
-26.21%
143.49
Selling And Marketing Expense
19.48
-9.13%
21.44
-35.04%
33.01
-7.68%
35.75
General And Administrative Expense
60.45
-6.23%
64.47
-11.55%
72.88
-32.36%
107.74
Salaries And Wages
46.53
-0.53%
46.78
-10.62%
52.34
-35.98%
81.76
Other Gand A
13.91
-21.32%
17.68
-13.92%
20.54
-20.95%
25.98
Total Expenses
188.56
-5.92%
200.43
-14.57%
234.61
-29.52%
332.89
Operating Income
-107.21
+17.27%
-129.59
+21.48%
-165.05
-34.20%
-122.99
Total Operating Income As Reported
-121.50
+7.01%
-130.65
+21.29%
-165.99
-34.57%
-123.34
EBITDA
-88.10
+14.17%
-102.65
+29.61%
-145.83
-35.40%
-107.70
Normalized EBITDA
-74.31
+27.55%
-102.57
+29.64%
-145.78
-59.97%
-91.12
Reconciled Depreciation
1.88
-42.74%
3.28
+0.28%
3.27
+36.81%
2.39
EBIT
-89.97
+15.06%
-105.92
+28.95%
-149.09
-35.43%
-110.09
Total Unusual Items
-13.79
-17137.50%
-0.08
-53.85%
-0.05
+99.69%
-16.57
Total Unusual Items Excluding Goodwill
-13.79
-17137.50%
-0.08
-53.85%
-0.05
+99.69%
-16.57
Special Income Charges
-13.12
0.00
0.00
+100.00%
-42.11
Other Special Charges
1.33
—
—
42.11
Impairment Of Capital Assets
5.75
—
—
—
Restructuring And Mergern Acquisition
6.03
—
—
—
Net Income
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Pretax Income
-141.61
+9.30%
-156.14
+20.10%
-195.42
-33.10%
-146.82
Net Non Operating Interest Income Expense
-42.82
-12.87%
-37.94
-6.02%
-35.78
-4.75%
-34.16
Interest Expense Non Operating
51.63
+2.83%
50.21
+8.39%
46.33
+26.12%
36.73
Net Interest Income
-42.82
-12.87%
-37.94
-6.02%
-35.78
-4.75%
-34.16
Interest Expense
51.63
+2.83%
50.21
+8.39%
46.33
+26.12%
36.73
Interest Income Non Operating
8.81
-28.21%
12.27
+16.43%
10.54
+310.44%
2.57
Interest Income
8.81
-28.21%
12.27
+16.43%
10.54
+310.44%
2.57
Other Income Expense
8.42
-26.08%
11.39
+110.34%
5.42
-47.58%
10.33
Other Non Operating Income Expenses
22.21
+93.59%
11.47
+109.80%
5.47
-79.67%
26.91
Gain On Sale Of Security
-0.67
-737.50%
-0.08
-53.85%
-0.05
-100.20%
25.54
Tax Provision
1.01
+511.45%
0.17
-99.58%
39.11
+17127.31%
0.23
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-2.90
-17137.50%
-0.02
-53.85%
-0.01
+99.69%
-3.48
Net Income Including Noncontrolling Interests
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Net Income From Continuing Operation Net Minority Interest
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Net Income From Continuing And Discontinued Operation
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Net Income Continuous Operations
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Normalized Income
-131.73
+16.51%
-157.78
+34.26%
-240.01
-66.63%
-144.04
Net Income Common Stockholders
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Diluted EPS
—
-1.62
+44.90%
-2.94
-47.74%
-1.99
Basic EPS
—
-1.62
+44.90%
-2.94
-47.74%
-1.99
Basic Average Shares
—
97.16
+18.91%
81.71
+4.55%
78.15
Diluted Average Shares
—
97.16
+18.91%
81.71
+4.55%
78.15
Diluted NI Availto Com Stockholders
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Earnings From Equity Interest
—
—
—
-10.08
Earnings From Equity Interest Net Of Tax
0.00
+100.00%
-1.54
+72.07%
-5.53
+45.18%
-10.08
Other Taxes
-1.17
-10.25%
-1.06
-13.69%
-0.94
-161.90%
-0.36
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
323.15
+0.36%
321.98
-9.25%
354.78
-27.72%
490.86
Current Assets
306.33
+5.18%
291.25
-13.39%
336.29
-22.69%
434.98
Cash Cash Equivalents And Short Term Investments
261.34
+4.17%
250.87
-9.95%
278.60
-14.66%
326.44
Cash And Cash Equivalents
261.34
+4.17%
250.87
-9.95%
278.60
-14.66%
326.44
Receivables
29.12
+43.32%
20.32
-19.32%
25.18
-65.49%
72.97
Accounts Receivable
29.12
+43.32%
20.32
-19.32%
25.18
-65.49%
72.97
Other Receivables
—
—
—
3.36
Taxes Receivable
—
—
—
0.76
Accrued Interest Receivable
—
—
—
0.62
Inventory
4.18
+85.87%
2.25
-86.09%
16.18
+33.99%
12.07
Work In Process
—
18.34
+13.94%
16.09
+33.49%
12.06
Finished Goods
—
0.05
-40.24%
0.08
+412.50%
0.02
Prepaid Assets
5.61
-32.95%
8.37
-19.08%
10.34
-55.60%
23.30
Other Current Assets
6.08
-35.62%
9.45
+57.76%
5.99
-74.51%
23.50
Total Non Current Assets
16.82
-45.27%
30.73
+66.17%
18.49
-66.91%
55.88
Net PPE
1.30
-90.34%
13.43
-16.76%
16.13
+57.24%
10.26
Gross PPE
2.68
-85.72%
18.75
-8.13%
20.41
+49.31%
13.67
Accumulated Depreciation
-1.38
+74.04%
-5.32
-24.44%
-4.28
-25.44%
-3.41
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.16
-45.14%
2.11
-8.07%
2.29
+6.65%
2.15
Construction In Progress
—
—
—
0.00
Other Properties
1.30
-89.84%
12.77
-9.84%
14.16
+50.08%
9.44
Leases
0.23
-94.19%
3.87
-2.02%
3.95
+89.87%
2.08
Goodwill And Other Intangible Assets
—
—
—
14.36
Other Intangible Assets
—
—
—
14.36
Investments And Advances
—
0.00
-100.00%
1.65
-78.37%
7.61
Long Term Equity Investment
—
0.00
-100.00%
1.65
-78.37%
7.61
Non Current Deferred Assets
—
—
0.00
-100.00%
37.10
Non Current Deferred Taxes Assets
—
—
0.00
-100.00%
37.10
Other Non Current Assets
15.52
-10.29%
17.30
+2332.77%
0.71
-21.18%
0.90
Total Liabilities Net Minority Interest
508.98
-2.98%
524.62
+4.29%
503.03
+22.27%
411.41
Current Liabilities
70.16
-12.81%
80.47
+18.91%
67.67
-17.41%
81.94
Payables And Accrued Expenses
43.49
-16.60%
52.15
-1.90%
53.16
-17.30%
64.28
Payables
9.18
-49.11%
18.03
+15.80%
15.57
+26.05%
12.35
Accounts Payable
9.18
-49.11%
18.03
+15.80%
15.57
+26.05%
12.35
Current Accrued Expenses
34.32
+0.58%
34.12
-9.24%
37.59
-27.61%
51.93
Employee Benefits
—
—
—
0.00
Total Tax Payable
—
—
—
0.00
Income Tax Payable
—
—
—
0.00
Current Debt And Capital Lease Obligation
3.54
+158.06%
1.37
-6.54%
1.47
+33.73%
1.10
Current Debt
3.00
—
—
12.47
Other Current Borrowings
3.00
—
—
12.47
Current Capital Lease Obligation
0.54
-60.76%
1.37
-6.54%
1.47
+33.73%
1.10
Other Current Liabilities
23.13
-14.16%
26.95
+106.66%
13.04
-21.25%
16.56
Total Non Current Liabilities Net Minority Interest
438.82
-1.20%
444.15
+2.02%
435.36
+32.14%
329.47
Long Term Debt And Capital Lease Obligation
113.49
-6.69%
121.63
-1.04%
122.91
+5.70%
116.28
Long Term Debt
112.45
-1.04%
113.63
+0.80%
112.73
+2.75%
109.71
Long Term Capital Lease Obligation
1.03
-87.07%
8.00
-21.46%
10.18
+55.09%
6.56
Non Current Pension And Other Postretirement Benefit Plans
—
—
—
0.00
Non Current Deferred Liabilities
322.52
+0.76%
320.09
+5.44%
303.57
+42.96%
212.35
Non Current Deferred Revenue
—
—
—
23.54
Other Non Current Liabilities
2.81
+15.50%
2.43
-72.60%
8.88
+959.55%
0.84
Stockholders Equity
-185.83
+8.29%
-202.64
-36.69%
-148.25
-286.59%
79.45
Common Stock Equity
-185.83
+8.29%
-202.64
-36.69%
-148.25
-286.59%
79.45
Capital Stock
11.08
+31.51%
8.43
+15.22%
7.31
+0.00%
7.31
Common Stock
11.08
+31.51%
8.43
+15.22%
7.31
+0.00%
7.31
Share Issued
128.31
+26.28%
101.61
+14.11%
89.04
+0.00%
89.04
Ordinary Shares Number
125.75
+27.20%
98.86
+20.13%
82.29
+2.05%
80.64
Treasury Shares Number
2.56
-6.69%
2.74
-59.33%
6.75
-19.65%
8.40
Additional Paid In Capital
1,439.75
+12.14%
1,283.89
+8.75%
1,180.55
+1.21%
1,166.41
Retained Earnings
-1,635.94
-9.55%
-1,493.32
-11.82%
-1,335.47
-21.91%
-1,095.42
Gains Losses Not Affecting Retained Earnings
-0.52
+63.62%
-1.42
-1427.96%
-0.09
-105.10%
1.82
Treasury Stock
0.20
-6.82%
0.22
-59.33%
0.54
-20.32%
0.68
Other Equity Adjustments
-0.52
+63.62%
-1.42
-1427.96%
-0.09
-105.10%
1.82
Total Equity Gross Minority Interest
-185.83
+8.29%
-202.64
-36.69%
-148.25
-286.59%
79.45
Total Capitalization
-73.38
+17.56%
-89.01
-150.60%
-35.52
-118.78%
189.16
Working Capital
236.17
+12.04%
210.78
-21.53%
268.62
-23.91%
353.04
Invested Capital
-70.38
+20.93%
-89.01
-150.60%
-35.52
-118.78%
189.16
Total Debt
117.02
-4.86%
123.00
-1.11%
124.38
+5.97%
117.38
Capital Lease Obligations
1.57
-83.22%
9.37
-19.58%
11.65
+52.03%
7.66
Net Tangible Assets
-185.83
+8.29%
-202.64
-36.69%
-148.25
-286.59%
79.45
Tangible Book Value
-185.83
+8.29%
-202.64
-36.69%
-148.25
-286.59%
79.45
Derivative Product Liabilities
—
—
—
1.79
Foreign Currency Translation Adjustments
—
—
—
-0.36
Investmentsin Joint Venturesat Cost
—
0.00
-100.00%
1.65
-78.37%
7.61
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-141.17
-14.00%
-123.83
-4.34%
-118.69
+14.19%
-138.31
Cash Flow From Continuing Operating Activities
-141.17
-14.00%
-123.83
-4.34%
-118.69
+14.19%
-138.31
Net Income From Continuing Operations
-142.62
+9.64%
-157.85
+34.25%
-240.05
-52.78%
-157.13
Depreciation Amortization Depletion
1.88
-42.74%
3.28
+0.28%
3.27
+36.81%
2.39
Depreciation
1.88
-42.74%
3.28
+0.28%
3.27
+36.81%
2.39
Amortization Cash Flow
—
—
—
0.12
Depreciation And Amortization
1.88
-42.74%
3.28
+0.28%
3.27
+36.81%
2.39
Amortization Of Intangibles
—
—
—
0.12
Other Non Cash Items
9.04
-47.66%
17.28
-0.14%
17.30
+168.11%
-25.41
Pension And Employee Benefit Expense
—
-0.19
+73.88%
-0.71
0.00
Stock Based Compensation
6.91
+5.13%
6.57
-51.33%
13.49
-72.64%
49.32
Asset Impairment Charge
8.98
+491.50%
1.52
-5.60%
1.61
-25.73%
2.17
Deferred Tax
—
0.00
-100.00%
37.10
+2388.96%
-1.62
Deferred Income Tax
—
0.00
-100.00%
37.10
+2388.96%
-1.62
Operating Gains Losses
—
1.54
-64.25%
4.32
-89.39%
40.69
Gain Loss On Investment Securities
—
-0.30
+40.44%
-0.50
+95.68%
-11.50
Net Foreign Currency Exchange Gain Loss
—
—
—
-0.11
Change In Working Capital
-25.36
-762.70%
3.83
-91.36%
44.27
+190.86%
-48.73
Change In Receivables
-8.79
-284.22%
4.77
-90.02%
47.79
+211.78%
-42.75
Changes In Account Receivables
-8.79
-284.22%
4.77
-90.02%
47.79
+211.78%
-42.75
Change In Inventory
-2.38
+36.13%
-3.73
+34.73%
-5.71
+40.81%
-9.65
Change In Prepaid Assets
5.23
+453.58%
-1.48
—
—
Change In Payables And Accrued Expense
-16.46
-221.00%
13.60
+223.99%
-10.97
-166.26%
16.56
Change In Accrued Expense
-7.42
-166.61%
11.14
+178.77%
-14.14
-187.06%
16.25
Change In Payable
-9.04
-467.10%
2.46
-22.41%
3.17
+923.55%
0.31
Change In Account Payable
-9.04
-467.10%
2.46
-22.41%
3.17
+923.55%
0.31
Change In Other Working Capital
—
—
—
1.85
Change In Other Current Assets
-0.05
+89.91%
-0.46
-106.09%
7.49
+164.15%
-11.67
Change In Other Current Liabilities
-2.91
+67.20%
-8.88
-256.53%
5.67
+571.74%
-1.20
Investing Cash Flow
0.40
+145.56%
-0.87
+73.04%
-3.22
-368.12%
-0.69
Cash Flow From Continuing Investing Activities
0.40
+145.56%
-0.87
+73.04%
-3.22
-368.12%
-0.69
Net PPE Purchase And Sale
0.40
+145.56%
-0.87
+73.04%
-3.22
-368.12%
-0.69
Purchase Of PPE
-0.26
+69.55%
-0.87
+73.04%
-3.22
-368.12%
-0.69
Sale Of PPE
0.66
0.00
—
—
Capital Expenditure
-0.26
+69.55%
-0.87
+73.04%
-3.22
-368.12%
-0.69
Net Intangibles Purchase And Sale
—
—
—
-1.72
Purchase Of Intangibles
—
—
—
-1.72
Net Other Investing Changes
—
—
—
-0.21
Financing Cash Flow
150.94
+55.53%
97.05
+31.38%
73.88
+8335.79%
-0.90
Cash Flow From Continuing Financing Activities
150.94
+55.53%
97.05
+31.38%
73.88
+8335.79%
-0.90
Net Issuance Payments Of Debt
—
—
0.00
-100.00%
115.60
Issuance Of Debt
—
—
0.00
-100.00%
115.60
Repayment Of Debt
—
—
—
-1.01
Long Term Debt Issuance
—
—
0.00
-100.00%
115.60
Long Term Debt Payments
—
—
—
-1.01
Net Long Term Debt Issuance
—
—
0.00
-100.00%
115.60
Net Common Stock Issuance
86.28
+42.60%
60.51
0.00
-100.00%
6.13
Common Stock Payments
—
—
—
-0.22
Repurchase Of Capital Stock
—
—
—
-0.22
Proceeds From Stock Option Exercised
66.18
+75.48%
37.71
+4778.53%
0.77
0.00
Net Other Financing Charges
-1.51
-30.18%
-1.16
-101.59%
73.10
+159.61%
-122.62
Changes In Cash
10.17
+136.77%
-27.65
+42.43%
-48.03
+65.67%
-139.90
Effect Of Exchange Rate Changes
0.30
+467.47%
-0.08
-145.11%
0.18
+188.46%
-0.21
Beginning Cash Position
250.87
-9.95%
278.60
-14.66%
326.44
-30.03%
466.54
End Cash Position
261.34
+4.17%
250.87
-9.95%
278.60
-14.66%
326.44
Free Cash Flow
-141.44
-13.42%
-124.70
-2.30%
-121.90
+12.30%
-139.00
Interest Paid Supplemental Data
14.47
-7.87%
15.70
+2.05%
15.39
+51.18%
10.18
Common Stock Issuance
86.28
+42.60%
60.51
0.00
-100.00%
6.13
Earnings Losses From Equity Investments
0.00
-100.00%
1.54
-72.07%
5.53
-45.18%
10.08
Interest Paid CFO
—
—
—
-10.37
Interest Received CFO
—
—
—
2.14
Issuance Of Capital Stock
86.28
+42.60%
60.51
0.00
-100.00%
6.13
Taxes Refund Paid
—
—
—
-13.47
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category